These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29161652)

  • 1. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
    Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
    Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
    Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
    Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.
    Gennari A; Nanni O; Puntoni M; DeCensi A; Scarpi E; Conte P; Antonucci G; Amadori D; Bruzzi P
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1862-7. PubMed ID: 23945199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis.
    Lv S; Wang Y; Sun T; Wan D; Sheng L; Li W; Zhu H; Li Y; Lu J
    Oncol Res Treat; 2018; 41(7-8):450-455. PubMed ID: 29902791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
    Olson EM; Najita JS; Sohl J; Arnaout A; Burstein HJ; Winer EP; Lin NU
    Breast; 2013 Aug; 22(4):525-31. PubMed ID: 23352568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Poggio F; Puglisi F; Bernardo A; Montemurro F; Poletto E; Pozzi E; Rossi V; Risi E; Lai A; Zanardi E; Sini V; Ziliani S; Minuti G; Mura S; Grasso D; Fontana A; Del Mastro L
    Oncologist; 2015 Aug; 20(8):880-9. PubMed ID: 26099741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
    Steenbruggen TG; Bouwer NI; Smorenburg CH; Rier HN; Jager A; Beelen K; Ten Tije AJ; de Jong PC; Drooger JC; Holterhues C; Kitzen JJEM; Levin M-; Sonke GS
    Breast Cancer Res Treat; 2019 Dec; 178(3):597-605. PubMed ID: 31493033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study.
    Aitelhaj M; Lkhoyaali S; Rais G; Boutayeb S; Errihani H
    Pan Afr Med J; 2016; 24():324. PubMed ID: 28154679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
    Murthy RK; Varma A; Mishra P; Hess KR; Young E; Murray JL; Koenig KH; Moulder SL; Melhem-Bertrandt A; Giordano SH; Booser D; Valero V; Hortobagyi GN; Esteva FJ
    Cancer; 2014 Jul; 120(13):1932-8. PubMed ID: 24677057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study.
    Xie Y; Ge R; Sang D; Luo T; Li W; Ji X; Yuan P; Wang B
    Cancer Med; 2020 May; 9(9):2981-2988. PubMed ID: 32108439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.
    Rugo HS; Brufsky AM; Ulcickas Yood M; Tripathy D; Kaufman PA; Mayer M; Yoo B; Abidoye OO; Yardley DA
    Breast Cancer Res Treat; 2013 Oct; 141(3):461-70. PubMed ID: 24062208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.